Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives; a case report

  • Thomas Idorn1Email author,
  • Lone Schejbel2,
  • Casper Rydahl3,
  • James Goya Heaf3,
  • Karen Riis Jølvig2,
  • Marie Bergstrøm2,
  • Peter Garred2 and
  • Anne-Lise Kamper1
BMC Nephrology201213:64

DOI: 10.1186/1471-2369-13-64

Received: 23 January 2012

Accepted: 26 July 2012

Published: 26 July 2012

Abstract

Background

Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy are rare diseases with no known coherence.

Case Presentation

A daughter and her biological mother were diagnosed with pregnancy-induced thrombotic microangiopathy and anti-glomerular basement membrane glomerulonephritis, respectively. Both developed end-stage renal disease. Exploration of a common aetiology included analyses of HLA genotypes, functional and genetic aspects of the complement system, ADAMTS13 activity and screening for autoantibodies.

The daughter was heterozygous carrier of the complement factor I G261D mutation, previously described in patients with membranoproliferative glomerulonephritis and atypical haemolytic uremic syndrome. The mother was non-carrier of this mutation. They shared the disease associated complement factor H silent polymorphism Q672Q (79602A>G).

Conclusion

An unequivocal functional or molecular association between these two family cases was not found suggesting that the patients probably share another, so far undiagnosed and unknown, predisposing factor. It seems highly unlikely that two infrequent immunologic diseases would occur by unrelated pathophysiological mechanisms within first degree relatives.

Keywords

Aetiology Anti-glomerular basement membrane glomerulonephritis Atypical haemolytic-uremic syndrome Thrombotic microangiopathy

Background

Goodpasture’s disease or anti-glomerular basement membrane glomerulonephritis (anti-GBMGN) has an incidence around one/million/year [1]. Autoantibodies are directed against epitope(s) in the glomerular basement membrane, in response to unknown stimuli [2]. It occurs in siblings and twins and a strong association with the major histocompatibility complex class II gene HLA DR2, different HLA DRB1 genes, HLA DR15 and DR4 has been reported, while DR1 and DR7 seem to protect [3, 4].

Thrombotic microangiopathy (TMA) is characterized by haemolytic anaemia, thrombocytopenia and organ injury due to platelet thrombosis in the microcirculation. Depending on predominantly kidney or CNS location, it is classified as haemolytic-uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). HUS may be typical HUS or atypical HUS (aHUS) including the pregnancy induced form. The incidence of acquired TMA is 17.5/million/year, 17% occur during pregnancy or postpartum [5]. aHUS has defects in complement regulation causing increased alternative pathway activation in glomerular vessels. The causes are disabling mutations in the genes of complement factor H (CFH), membrane cofactor protein (MCP; CD46), complement factor I (CFI) and thrombomodulin (THBD), and enabling mutations in factor B and C3 [6]. Autoantibodies against CFH sometimes occur [7]. Dense deposit disease (formerly membranoproliferative glomerulonephritis type II) and C3 glomerulonephritis are also associated with uncontrolled complement activation and mutations in CFH or CFI have been described [8]. The same mutations have occasionally been found in both C3 glomerulonephritis and aHUS [9]. This, in combination with incomplete penetrance of aHUS, indicates that other genetic or environmental factors trigger these diseases.

Anti-GBMGN has been associated with TMA (in particular TTP) and immune complex glomerulonephritis. Both diseases were diagnosed in the same person, typically with TMA diagnosed shortly after anti-GBMGN debut [10, 11]. To our knowledge anti-GBMGN has never been associated with aHUS and anti-GBMGN and TMA has never been described within families. We present a daughter and her biological mother diagnosed with pregnancy-induced TMA and anti-GBMGN respectively, with 14 years in between and describes our exploration of a suspected link between these two rare diseases.

Case presentation

Daughter

A 22-year-old female was admitted with acute kidney failure following abruptio placentae causing severe vaginal haemorrhage in gestation week 33, resulting in stillbirth. The patient had a history of abortions in gestation weeks 9 and 28. Placental infarction at the second miscarriage resulted in heparin treatment during the actual pregnancy, which had been normotensive without proteinuria 2 days before admission.

She presented with haemolytic anaemia, thrombocytopenia, schistocytes, uraemia, hypertension, oliguria and proteinuria (Table 1). Treatment included plasmapheresis, haemodialysis and glucocorticoids. Anti-cardiolipin immunoglobulins, anti-Scl-70 and anti-double stranded DNA were negative. Anti-GBM and ANCA titers were not examined at disease onset, but were negative when examined 14 years later. Renal biopsy showed necrotic glomeruli with thrombi, platelet deposits and fibrin, vascular changes with luminal narrowing and intimal thickening, but no deposits. The diagnosis was TMA (pathologist Thomas Horn, MD, DMSc, Herlev Hospital, Denmark) (Figure 1). A grand mal seizure occurred during hospitalization (no simultaneous metabolic derangements or severe hypertension). The clinical diagnosis was pregnancy-induced TMA with components of aHUS and TTP. After 6 months, kidney function improved and the patient was temporarily dialysis-independent for three years. She was never transplanted.
Table 1

Baseline data

Compound and Unit – SI units

Reference

Daughter, (TMA/aHUS)

Mother, (anti-GBMGN)

Haemoglobin, mmol/L (g/L)

7.0–10.0 (113–161)

5.3 (85)

6.1 (98)

Platelets, ×109/L

150–400

46

533

Haptoglobin, μmol/L

4–23

<5

13

Lactate dehydrogenase, U/L

150–450

7724

313

Bilirubin, μmol/L

4–17

36

9

Peripheral smear

 

>5% Schistocytes (Coombs test not performed)

n/a

White blood cell count × 109/L

3.0–9.0

18.3

21.0

C-reactive protein, nmol/L

<95

n/a

981

Activated partial thromboplastin time, seconds

23–35

49

26

Factor II + VII + X, U/L

>0.60

1.00

0.85

Creatinine, μmol/L

40–110

430

799

Urea nitrogen, mmol/L

2.5–7.5

15.0

30.7

Potassium, mmol/L

3.5–5.0

6.6

5.9

Sodium, mmol/L

136–146

137

131

Phosphorus (inorganic), mmol/L

0,80–1,50

1,99

2,37

Calcium, mmol/L

2,20–2,60

2,18

2,15

Albumin, g/L

36–48

28

37

Bicarbonate, mmol/L

23–31

20

21

Baseline data at admission. Reference interval according to Danish standards.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-13-64/MediaObjects/12882_2012_Article_287_Fig1_HTML.jpg
Figure 1

TMA/aHUS. Light microscopy, x200, hematoxylin and eosin stain. Thrombosis of the afferent arteriole (, large arrow) and partial necrosis of the glomerulus with deposition of fibrin (*) and fragmented erythrocytes (, small arrow).

Mother

A 69-year-old female was admitted with anuria and acute kidney failure. The patient had a 6-year hypertension history, hypothyroidism for 30 years and a minor stroke 4 months earlier treated by carotid thrombendarterectomy. At that time p-creatinine was normal. Blood tests showed severe uraemia and anaemia, but no haemolysis (Table 1). The anti-GBM titer was positive, 95 U/mL (ELISA-kit, Wieslab, Sweden; ELISA-reader TECAN, Switzerland) and myeloperoxidase anti-neutrophil cytoplasmic antibodies titer (MPO ANCA) was 25 U/mL. Proteinase-3 ANCA was negative (ELISA-reader TECAN, Switzerland) and chest X-ray normal. Treatment included methylprednisolone, cyclophosphamide, plasmapheresis and haemodialysis. Renal biopsy showed diffuse extracapillary glomerulonephritis with predominantly fresh crescentic formations, focal and segmental necrosis and linear deposition of IgG along the glomerular basement membrane, consistent with anti-GBMGN (pathologist Claus B. Andersen MD, DMSc, Rigshospitalet, Denmark) (Figure 2). The anti-GBM and MPO ANCA titres normalised after 16 days. There were no signs of TMA at any time. Kidney function was not regained.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2369-13-64/MediaObjects/12882_2012_Article_287_Fig2_HTML.jpg
Figure 2

anti-GBMGN. Light microscopy, x200, hematoxylin and eosin stain. Diffuse extracapillary glomerulonephritis with predominant fresh crescentic formations (*) and a few older cresentic formations with fibrosis (**). Compression of the preserved part of glomeruli ().

Additional analyses

Following maternal diagnosis, additional information was obtained and the following analyses were done:

Family history: Further elaboration of the family history of kidney disease was done in order to identify additional cases. No other family members had ever experienced clinically significant kidney diseases or any signs of kidney disease. It was not possible to obtain blood samples for genetic analyses from the father. Mother and daughter lived in the same household until a few years before disease onset of the daughter. There were no obvious exposures to environmental factors such as drugs, hydrocarbons or other toxins. They discharged different occupations.

HLA tissue typing (Dynabeads, Dynal, Norway): HLA-A1,26;B7,8;DR2,3 (mother), HLA-A1;B8,37;Cw6;DR3,6 (daughter). Subtyping was not performed.

ADAMTS13 activity and antibodies (CytoFlour® 4000 Fluorescence Plate Reader, Applied Biosystems Inc, USA): ADAMTS13-protein 0.61 U/L (0.75-1.33) (mother); 0.97 U/L (daughter). No antibodies.

The complement system (Wielisa, Wieslab, Sweden): Both patients had normal alternative- and classical pathway function. The daughter had reduced Mannose-binding lectin (MBL) pathway activity, and additional gene typing (SSP-PCR) revealed gene type XA/B, compatible with a severely reduced MBL level. Gene sequencing of CFH, CFI, MCP and THBD showed heterozygosity for a CFI mutation (G261D, alternative syntax G243D) and several disease risk associated polymorphisms in the daughter. The mother was non-carrier of the G261D mutation but shared the disease associated CFH Q672Q silent polymorphism (Table 2). CFH-autoantibodies were not investigated, but none of the patients were carriers of the common CFHR1/CFHR3 deletion or other CFHR1 deletions strongly associated with antibody induced aHUS [12]. Measurement of C3 levels were not performed.
Table 2

Genetic analyses

Gene

Variation

Description

Disease association

Daughter, (TMA/aHUS)

Mother (anti-GBMGN)

CFI

NG_007569

    
 

c.5256A>G

Intron rs7671905

Polymorphism

homozygous

homozygous

 

c.42455C>T

Intron rs79375065

Polymorphism

heterozygous

Non-carrier

 

c.46524G>A

Intron rs4382037

Polymorphism

homozygous

homozygous

 

c.46615G>A

G261D

Mutation reported in MPGN and aHUS

heterozygous

Non-carrier

 

c.49140C>A

Intron rs7437142

Polymorphism

homozygous

homozygous

 

c.49159ins AATTT

Intron rs78629056

Polymorphism

homozygous

homozygous

 

c.57335C>G

Intron rs7441380

Polymorphism

homozygous

homozygous

 

c.66205C>T

Intron rs551

Polymorphism

homozygous

homozygous

CFH

NG_007259.1

    
 

c.38184A>C

A307A

Disease risk polymophism (AMD)

heterozygous

Non-carrier

 

c.43097C>T

H402Y

Disease risk polymophism (AMD)

heterozygous

Non-carrier

 

c.79602A>G

Q672Q

Disease risk polymorphism (aHUS)

heterozygous

heterozygous

 

c.89786C>A

Intron rs375046

Polymorphism

heterozygous

heterozygous

 

c.93634G>T

E936D

Disease risk polymorphism (aHUS)

heterozygous

Non-carrier

MCP

NG_009296

    
 

c.12610A>G

L139L rs12126088

Rare non-Disease Causing Polymorphism

heterozygous

Non-carrier

 

c.20790G>T

Intron rs2724374

Polymorphism

heterozygous

Non-carrier

 

c.36158G>A

Intron rs1962149

Polymorphism

heterozygous

Non-carrier

THBD

NG_012027

    
 

c.6578C>T

A473V rs1042579

Polymorphism

homozygous

heterozygous

Genetic screening for variation in the CFI-, CFH-, MCP- (CD46) and THBD-genes. Position of the variations in the respective GeneBank refrence sequences as well as dbSNP numbers are listed.

CFI = Complement Factor I, CFH = Complement Factor H, MCP = Membrane Cofactor Protein, THBD = Thrombomodulin, AMD = Age-related Macula Degeneration.

Conclusions

The occurrence of two very rare renal diseases within the same family is likely to be explained by a common aetiology. One linkage could be a common autoantibody-profile; however this was not demonstrated. ANCA-positive testing in anti-GBMGN occurs in 30% [13] and HLA tissue typing demonstrated known predisposing relations without any conspicuous shared patterns. The mother’s slightly reduced ADAMTS13-protein is probably not significant. However, the daughter’s normal ADAMTS13 activity and antibody absence during screening, does not exclude affection at diagnosis. The daughter’s G261D CFI-gene mutation combined with disease-associated polymorphisms may predispose to the pregnancy-induced TMA. The G261D mutation has been found in other patients with C3 glomerulonephritis and aHUS [9, 14]. Despite several tests by Nilsson et al., no functional effect of the G261D mutation on CFI mediated complement regulation or on CFI serum levels could be demonstrated [14]; however, it may have effects not revealed by the in vitro tests, or be a marker for a linked genetic deficiency. The silent G672G polymorphism in both patients is strongly associated with aHUS [15], and even though this is unlikely to be the shared aetiology, it is possible that it influenced the disease in both patients. Reduced MBL activity was demonstrated in the daughter but not the mother. This has no known relation to TMA (or anti-GBMGN).

In conclusion, we have found a shared CFH polymorphism that may confer increased complement-mediated disease risk, but no other connection between TMA and anti-GBMGN. The diseases may require multiple triggers including mutations, polymorphisms, autoantibodies and perhaps infections, and a common genetic susceptibility cannot be ruled out.

Consent

Written informed consent was obtained from both patients for publication of this case report and accompanying images of the kidney biopsies. Acceptance was noted in the patients’ records. A copy of the written consent is available for review by the Editor-in Chief of BMC Nephrology.

Abbreviations

anti-GBMGN: 

Anti-glomerular basement membrane glomerulonephritis

TMA: 

Thrombotic microangiopathy

TTP: 

Thrombotic thrombocytopenic purpura

aHUS: 

Atypical HUS

CFH: 

Complement factor H

CFI: 

Complement factor I

MCP: 

Membrane cofactor protein

THBD: 

Thrombomodulin.

Declarations

Acknowledgements

None. Financial support was not applied for.

Authors’ Affiliations

(1)
Department of Nephrology, Rigshospitalet, University of Copenhagen
(2)
Department of Clinical Immunology, Rigshospitalet, University of Copenhagen
(3)
Department of Nephrology, Herlev Hospital, University of Copenhagen

References

  1. Bolton WK: Goodpasture’s syndrome. Kidney Int. 1996, 50: 1753-1766. 10.1038/ki.1996.495.View ArticlePubMedGoogle Scholar
  2. Pusey CD: Anti-glomerular basement membrane disease. Kidney Int. 2003, 64: 1535-1550. 10.1046/j.1523-1755.2003.00241.x.View ArticlePubMedGoogle Scholar
  3. Phelps RG, Rees AJ: The HLA complex in Goodpasture’s disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 1999, 56: 1638-1653. 10.1046/j.1523-1755.1999.00720.x.View ArticlePubMedGoogle Scholar
  4. Rees AJ, Peters DK, Compston DA, Batchelor JR: Strong association between HLA-DRW2 and antibody-mediated Goodpasture’s syndrome. Lancet. 1978, 1: 966-968.View ArticlePubMedGoogle Scholar
  5. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN: The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005, 3: 1432-1436. 10.1111/j.1538-7836.2005.01436.x.View ArticlePubMedGoogle Scholar
  6. Kavanagh D, Goodship T: Genetics and complement in atypical HUS. Pediatr Nephrol. 2010, 25: 2431-2442. 10.1007/s00467-010-1555-5.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al: Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010, 115: 379-387. 10.1182/blood-2009-05-221549.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Zipfel PF, Smith RJ, Skerka C: Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane. Nephrol Dial Transplant. 2009, 24: 385-387.View ArticlePubMedGoogle Scholar
  9. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al: Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007, 44: 193-199.View ArticlePubMedGoogle Scholar
  10. Borza DB, Netzer KO, Leinonen A, Todd P, Cervera J, Saus J, et al: The goodpasture autoantigen. Identification of multiple cryptic epitopes on the NC1 domain of the alpha3(IV) collagen chain. J Biol Chem. 2000, 275: 6030-6037. 10.1074/jbc.275.8.6030.View ArticlePubMedGoogle Scholar
  11. Torok N, Niazi M, Al AY, Taleb M, Taji J, Assaly R: Thrombotic thrombocytopenic purpura associated with anti-glomerular basement membrane disease. Nephrol Dial Transplant. 2010, 25: 3446-3449. 10.1093/ndt/gfq437.View ArticlePubMedGoogle Scholar
  12. Zipfel PF, Mache C, Muller D, Licht C, Wigger M, Skerka C: DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol. 2010, 25: 2009-2019. 10.1007/s00467-010-1446-9.View ArticlePubMedGoogle Scholar
  13. Jayne DR, Marshall PD, Jones SJ, Lockwood CM: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990, 37: 965-970. 10.1038/ki.1990.72.View ArticlePubMedGoogle Scholar
  14. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, et al: A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol. 2007, 44: 1835-1844. 10.1016/j.molimm.2006.10.005.View ArticlePubMedGoogle Scholar
  15. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, et al: Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003, 12: 3385-3395. 10.1093/hmg/ddg363.View ArticlePubMedGoogle Scholar
  16. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/64/prepub

Copyright

© Idorn et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.